T 2355/18 (RGM inhibiting substances/MITSUBISHI TANABE) of 07.04.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T235518.20220407
- Date of decision
- 7 April 2022
- Case number
- T 2355/18
- Online on
- 24 May 2022
- Petition for review of
- -
- Application number
- 10835979.5
- IPC class
- C07K 16/18C07K 16/28A61K 31/7088C12N 15/113A61K 45/00A61K 33/00A61K 31/355A61K 39/395A61K 33/04A61K 33/26A61K 39/00A61P 43/00A61K 31/375A61K 33/06A61K 31/07A61K 31/122C07K 16/22A61K 33/30
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- T CELL ACTIVATION INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND SCREENING METHOD FOR T CELL ACTIVATION INHIBITING SUBSTANCE
- Applicant name
- Mitsubishi Tanabe Pharma Corporation
- Opponent name
- AbbVie Inc.
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)
- Keywords
- Grounds for opposition - added subject-matter (yes)
Amendments - allowable (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appealed decision is set aside.
2. The patent is revoked.